VAM
JBIO icon

Vazirani Asset Management’s Jade Biosciences JBIO Stock Holding History

Vazirani Asset Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,143
Closed -$199K – 16
2024
Q4 		$199K Buy
+2,143
New +$185K 0.62% 15

Other funds holding JBIO

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
AI
Allostery Investments Stamford, Connecticut $7.85M AUM
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vazirani Asset Management's JBIO Position: Q1 2025 in Review

Vazirani Asset Management sold out of Jade Biosciences (JBIO) in Q1 2025, closing a stake of 2,143 shares — an estimated $199K sold.

Vazirani Asset Management first reported a position in JBIO in Q4 2024 and held it in 1 quarter. The position peaked at $199K in Q4 2024. 78 funds tracked by Wall St. Rank hold JBIO as of Q1 2025.

  • Vazirani Asset Management reported no remaining Jade Biosciences position as of Q1 2025 after selling out during the quarter.
  • Vazirani Asset Management sold 2,143 Jade Biosciences shares in Q1 2025, an estimated $199K.
  • Vazirani Asset Management first reported a position in Jade Biosciences in Q4 2024 and held it in 1 quarter.
  • Vazirani Asset Management's Jade Biosciences position peaked at $199K in Q4 2024.
  • 78 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2025.

Based on Vazirani Asset Management's 13F filing for Q1 2025, filed 15 May 2025.